Skip to main navigation Skip to search Skip to main content

Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis

  • Jiupeng Zhou
  • , Hui Guo
  • , Yongfeng Zhang
  • , Heng Liu
  • , Quanli Dou
  • Xi'an Chest Hospital
  • The First Affiliated Hospital of Xi’an Jiaotong University

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Purpose: The aim of this Network Meta-analysis was to compare the current radiotherapy regimens of limited-stage small cell lung cancer (LS-SCLC), in terms of overall survival (OS), progression-free survival (PFS), and the incidence of acute radioactive esophagitis and radioactive pneumonia. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were comprehensively searched until January 2022. The studies were included, comparing radiotherapy regimens in LS-SCLC patients. We compared hypofractionated radiotherapy (HypoTRT), hyperfractionated radiotherapy (HyperTRT), and conventionally fractionated radiotherapy (ConvTRT1(<60 Gy), ConvTRT2(≥60 Gy)). Results: There was similar efficacy among the contemporary radiotherapy regimens for PFS of LS-SCLC. HypoTRT and HyperTRT significantly improved the OS of LS-SCLC compared with ConvTRT1 (<60 Gy), while not improving the OS of LS-SCLC compared with ConvTRT2 (≥60 Gy). There was no significant difference between HypoTRT and HyperTRT, between ConvTRT1(<60 Gy) and ConvTRT2(≥60 Gy), respectively. HyperTRT developed the highest odds of acute radioactive esophagitis compared to ConvTRT1(<60 Gy) and ConvTRT2(≥60 Gy). There was no significant difference in the incidence of acute radioactive esophagitis between HypoTRT and HyperTRT, ConvTRT1(<60 Gy), ConvTRT2(≥60 Gy), respectively and between ConvTRT1 and ConvTRT2. There was no statistically significant difference among radiotherapy regimens for the incidence of acute radioactive pneumonia. Conclusion: The current radiotherapy regimens are similar in efficacy and toxicity for LS-SCLC, except for ConvTRT1(<60 Gy). Given the lower costs and convenient logistics management of HypoTRT comparatively, it is an acceptable alternative for LS-SCLC.

Original languageEnglish
Pages (from-to)4214-4224
Number of pages11
JournalCancer Medicine
Volume11
Issue number22
DOIs
StatePublished - Nov 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • effectiveness
  • limited-stage small cell lung cancer
  • network meta-analysis
  • radiotherapy regimens
  • toxicity

Fingerprint

Dive into the research topics of 'Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis'. Together they form a unique fingerprint.

Cite this